Anemia Management News

DALLAS — A study shows that ferric pyrophosphate citrate administered via intraperitoneal delivery can successfully meet iron requirements for patients on PD.

DALLAS — Use of IV iron in patients with anemia on hemodialysis reduces the need for erythropoiesis-stimulating agents and effectively increases hemoglobin, according to a speaker at the Annual Dialysis Conference. According to another speaker, hypoxia-inducible factor prolyl hydroxylase inhibitors may also provide similar benefits.

A re-analysis of data from the results of the Proactive IV Iron Therapy in Haemodialysis Patients trial, originally presented at a High Impact Clinical Trial Session during Kidney Week 2018, shows that higher iron stores in patients with ESRD not only help reduce the dosing levels for erythropoiesis-stimulating agents needed to treat anemia but also prove more effective in reducing cardiovascular-related hospitalizations and the risk of myocardial infarction compared with lower iron levels.

SAN DIEGO — A look at the cardiovascular safety and efficacy of methoxy polyethylene glycol-epoetin beta in the treatment of anemia in patients with chronic kidney disease showed no differences compared to a control group, according to findings presented at ASN Kidney Week 2018.

SAN DIEGO — A restrictive threshold approach to meeting red blood cell transfusion requirements can be as safe as a liberal approach for the risk of acute kidney injury in patients who undergo cardiac surgery, according to research presented at the ASN Kidney Week 2018.

Mycophenolic acid C12 to be associated with the 12-hour area under the curve, and linked to renal flare, infection and anemia, according to findings published in Nephrology Dialysis Transplantation.

Fishbane S, et al. Clin J Am Soc Nephrol. 2018;doi.org/10.2215/CJN.11631017.

Use of erythropoiesis-stimulating agents in patients with pre-dialysis CKD was rare and directed toward older, sicker patients who had high rates of death and cardiovascular events, according to a review of electronic health care records and claims data of a large managed care provider in the United States.

Akebia Therapeutics Inc. and Keryx Biopharmaceuticals Inc. have approved a definitive merger agreement under which the companies will combine in an all-stock agreement. The new company will be named Akebia Therapeutics Inc. and company executives say the transaction should be completed by the end of the year.

Research that will appear in the Journal of the American Society of Nephrology provided insights on the genetics underlying nephrotic syndrome in children and could lead to new diagnostic tests and treatments.